Abstract
Purpose
We prospectively evaluated the impact of transurethral resection of the prostate (TURP) versus superselective α-adrenergic blocker treatment on health-related quality of life (HRQOL) in men with clinically diagnosed benign prostatic hyperplasia (BPH).
Patients and methods
A total of 219 patients with lower urinary tract symptoms (LUTS) caused by BPH were recruited in this study. Treatment modalities consisted of standard TURP (n = 104) and tamsulosin medical treatment (n = 115). HRQOL was assessed by SF-36-Item Health Survey 1.0. LUTS were estimated by The International Prostate Symptom Score. Patients’ outcome 4 weeks after treatment was compared to pre-treatment status and to that of the other group. Statistically significant changes in each HRQOL scale from baseline to follow-up period were investigated.
Results
Baseline characteristics were similar in both groups except for the duration of disease before treatment that was longer in TURP group. Both treatments resulted in statistically significant improvements from pre-treatment in all scales of QOL after 4 weeks, with no significant differences observed between the two groups. In medical treatment group, there was a significant association between higher educational level and better QOL in all 8 scales. Our outcomes revealed a significant decrease in the IPSS in both groups but this improvement was more evident in TURP group.
Conclusion
All scales concerning HRQOL were favorably improved 4 weeks after both surgical and medical treatment, and no significant differences were observed between these two treatment modalities for patients with symptomatic BPH. This information may aid patients when deciding which treatment option to take.
Similar content being viewed by others
References
Chute, C. G., Panser, L. A., Girman, C. J., et al. (1993). The prevalence of prostatism: A population-based survey of urinary symptoms. Journal of Urology, 150, 85–89.
Chow, R. D. (2001). Benign prostatic hyperplasia. Patient evaluation and relief of obstructive symptoms. Geriatrics, 56, 33–38.
Eckhardt, M. D., van Venrooij, G. E., van Melick, H. H., & Boon, T. A. (2001). Prevalence and bothersomeness of lower urinary tract symptoms in benign prostatic hyperplasia and their impact on well-being. Journal of Urology, 166, 563–568.
Bruskewitz, R. C. (2003). Quality of life and sexual function in patients with benign prostatic hyperplasia. Rev Urol, 5, 72–80.
Kaplan, S. A. (2005). Benign prostatic hyperplasia: Patient perceptions and financial reality regarding the aging American prostate. Journal of Urology, 173, 1852.
Arai, Y., Aoki, Y., Okubo, K., et al. (2000). Impact of interventional therapy for benign prostatic hyperplasia on quality of life and sexual function: A prospective study. Journal of Urology, 164, 1206–1211.
O’Leary, M. P., Roehrborn, C., Andriole, G., et al. (2003). Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor. BJU International, 92, 262–266.
Roehrborn, C. G., Van Kerrebroeck, P., & Nordling, J. (2003). Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: A pooled analysis of three double-blind, placebo-controlled studies. BJU International, 92, 257–261.
Narayan, P., Evans, C. P., & Moon, T. (2003). Long-term safety and efficacy of tamsulosin for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. Journal of Urology, 170, 498–502.
Cambio, A. J., & Evans, C. P. (2007). Outcomes and quality of life issues in the pharmacological management of benign prostatic hyperplasia (BPH). Therapeutics and Clinical Risk Management, 3, 181–196.
Suzuki, H., Yano, M., Awa, Y., et al. (2006). Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: Using international prostate symptom score and rand medical outcomes study 36-item health survey. International Journal of Urology, 13, 1202–1206.
Narayan, P., & Lepor, H. (2001). Long-term, open-label, phase III multicenter study of tamsulosin in benign prostatic hyperplasia. Urology, 57, 466–470.
Boyd, S. D., & Narayan, P. (1994). Management of benign prostatic hyperplasia. Western Journal of Medicine, 160, 165–166.
Soderdahl, D. W., Knight, R. W., & Hansberry, K. L. (1996). Erectile dysfunction following transurethral resection of the prostate. Journal of Urology, 156, 1354–1356.
Deliveliotis, C., Liakouras, C., Delis, A., et al. (2004). Prostate operations: Long-term effects on sexual and urinary function and quality of life. Comparison with an age-matched control population. Urological Research, 32, 283–289.
Ware, J. E., Jr, & Gandek, B. (1998). Overview of the SF-36 health survey and the international quality of life assessment (IQOLA) project. Journal of Clinical Epidemiology, 51, 903–912.
Montazeri, A., Goshtasebi, A., Vahdaninia, M., & Gandek, B. (2005). The short form health survey (SF-36): Translation and validation study of the Iranian version. Quality of Life Research, 14, 875–882.
Bosch, J. L., Hop, W. C., Kirkels, W. J., & Schroder, F. H. (1995). The international prostate symptom score in a community-based sample of men between 55 and 74 years of age: Prevalence and correlation of symptoms with age, prostate volume, flow rate and residual urine volume. British Journal of Urology, 75, 622–630.
Salinas-Sanchez, A. S., Hernandez-Millan, I., Lorenzo-Romero, J. G., et al. (2001). Quality of life of patients on the waiting list for benign prostatic hyperplasia surgery. Quality of Life Research, 10, 543–553.
O’Sullivan, M., Murphy, C., Deasy, C., et al. (2004). Effects of transurethral resection of prostate on the quality of life of patients with benign prostatic hyperplasia. Journal of the American College of Surgeons, 198, 394–403.
Donovan, J. L., Peters, T. J., Neal, D. E., et al. (2000). A randomized trial comparing transurethral resection of the prostate, laser therapy and conservative treatment of men with symptoms associated with benign prostatic enlargement: The CLasP study. Journal of Urology, 164, 65–70.
Gacci, M., Bartoletti, R., Figlioli, S., et al. (2003). Urinary symptoms, quality of life and sexual function in patients with benign prostatic hypertrophy before and after prostatectomy: A prospective study. BJU International, 91, 196–200.
Tascı, A. I., Ilbey, Y. O., Tugcu, V., et al. (2011). Transurethral resection of the prostate with monopolar resectoscope: Single-surgeon experience and long-term results of after 3589 procedures. Urology, 78, 1151–1155.
Acknowledgments
This research was supported by the Shiraz University of Medical Sciences. It was extracted from the dissertation NO. 90-5265. We thank Pamela Waltl (AuthorAID in the Eastern Mediterranean) for improving the use of English in the manuscript.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hadi, N., Aminsharifi, A., Sadeghi, A. et al. Superselective α-adrenergic blockers versus transurethral resection of the prostate: a prospective comparison of health-related quality of life outcome after treating patients with benign prostatic hyperplasia. Qual Life Res 22, 1287–1293 (2013). https://doi.org/10.1007/s11136-012-0259-7
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11136-012-0259-7